NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace - Update
NeuroOne Medical Technologies (Nasdaq: NMTC) CEO Dave Rosa appeared on Today's Marketplace alongside Dr. Jessica Clark to discuss advancements in epilepsy treatment and the company's OneRF® Ablation System. The system, which is the first and only FDA 510(k)-cleared device of its kind, combines the ability to record brain activity and perform RF ablation using a single device.
The OneRF® system consists of three main components: an electrode for stimulation, recording, and ablation; a temperature probe; and a radio frequency heat generator system. This innovation addresses a significant medical need, as over 50 million people worldwide suffer from epilepsy, with approximately one-third of patients experiencing medication-resistant seizures.
NeuroOne Medical Technologies (Nasdaq: NMTC) il CEO Dave Rosa è apparso su Today's Marketplace insieme alla Dr.ssa Jessica Clark per discutere i progressi nel trattamento dell'epilessia e del OneRF® Ablation System dell'azienda. Questo sistema, che è il primo e unico dispositivo di questo tipo approvato dalla FDA 510(k), combina la capacità di registrare l'attività cerebrale e di eseguire ablazione RF utilizzando un unico dispositivo.
Il sistema OneRF® è composto da tre componenti principali: un elettrodo per stimolazione, registrazione e ablazione; una sonda di temperatura; e un sistema generatore di calore a radiofrequenza. Questa innovazione risponde a un'importante esigenza medica, poiché oltre 50 milioni di persone in tutto il mondo soffrono di epilessia, con circa un terzo dei pazienti che sperimenta crisi resistenti ai farmaci.
NeuroOne Medical Technologies (Nasdaq: NMTC) el CEO Dave Rosa apareció en Today's Marketplace junto a la Dra. Jessica Clark para discutir los avances en el tratamiento de la epilepsia y el OneRF® Ablation System de la compañía. Este sistema, que es el primer y único dispositivo de su tipo aprobado por la FDA 510(k), combina la capacidad de registrar la actividad cerebral y realizar ablación por RF utilizando un solo dispositivo.
El sistema OneRF® consta de tres componentes principales: un electrodo para estimulación, grabación y ablación; una sonda de temperatura; y un sistema generador de calor por radiofrecuencia. Esta innovación aborda una necesidad médica significativa, ya que más de 50 millones de personas en todo el mundo sufren de epilepsia, con aproximadamente un tercio de los pacientes experimentando convulsiones resistentes a la medicación.
NeuroOne Medical Technologies (Nasdaq: NMTC)의 CEO인 Dave Rosa는 Today's Marketplace에 Dr. Jessica Clark와 함께 출연하여 간질 치료의 발전과 회사의 OneRF® Ablation System에 대해 논의했습니다. 이 시스템은 FDA 510(k) 승인을 받은 유일한 장치로, 단일 장치를 사용하여 뇌 활동을 기록하고 RF 절제를 수행하는 기능을 결합합니다.
OneRF® 시스템은 자극, 기록 및 절제를 위한 전극, 온도 프로브, 그리고 라디오 주파수 열 발생기 시스템의 세 가지 주요 구성 요소로 이루어져 있습니다. 이 혁신은 전 세계적으로 5천만 명 이상이 간질로 고통받고 있으며, 약 3분의 1의 환자가 약물 저항성 발작을 경험하는 중대한 의료적 필요를 해결합니다.
NeuroOne Medical Technologies (Nasdaq: NMTC) le PDG Dave Rosa est apparu sur Today's Marketplace aux côtés de la Dr. Jessica Clark pour discuter des avancées dans le traitement de l'épilepsie et du OneRF® Ablation System de l'entreprise. Ce système, qui est le premier et unique dispositif de ce type approuvé par la FDA 510(k), combine la capacité d'enregistrer l'activité cérébrale et de réaliser une ablation RF à l'aide d'un seul appareil.
Le système OneRF® se compose de trois composants principaux : un électrode pour la stimulation, l'enregistrement et l'ablation ; une sonde de température ; et un système générateur de chaleur par radiofréquence. Cette innovation répond à un besoin médical important, car plus de 50 millions de personnes dans le monde souffrent d'épilepsie, avec environ un tiers des patients présentant des crises résistantes aux médicaments.
NeuroOne Medical Technologies (Nasdaq: NMTC) CEO Dave Rosa trat auf Today's Marketplace zusammen mit Dr. Jessica Clark auf, um über Fortschritte in der Behandlung von Epilepsie und das OneRF® Ablation System des Unternehmens zu sprechen. Dieses System ist das erste und einzige FDA 510(k)-genehmigte Gerät seiner Art und kombiniert die Möglichkeit, Gehirnaktivität aufzuzeichnen und RF-Ablationen mit einem einzigen Gerät durchzuführen.
Das OneRF®-System besteht aus drei Hauptkomponenten: einer Elektrode zur Stimulation, Aufzeichnung und Ablation; einer Temperatursonde; und einem Hochfrequenzwärmegenerator-System. Diese Innovation adressiert einen erheblichen medizinischen Bedarf, da weltweit über 50 Millionen Menschen an Epilepsie leiden, wobei etwa ein Drittel der Patienten medikamentenresistente Anfälle hat.
- First and only FDA 510(k)-cleared device combining brain activity recording and RF ablation
- Addresses large market of 50 million epilepsy patients worldwide
- Potential expansion into pain management applications
- Reduces need for multiple invasive surgeries
- None.
EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on Today’s Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements in epilepsy treatment and NeuroOne’s breakthrough OneRF® Ablation System.
The full interview can be viewed online here.
Over 50 million people worldwide are affected by epilepsy, with nearly one-third of patients experiencing seizures that do not respond to medication. For these individuals, alternative treatment options, including Radiofrequency (RF) ablation therapy, offer a promising solution.
NeuroOne’s OneRF® ablation system, is the first and only FDA 510(k)-cleared device capable of both recording brain activity and performing an RF ablation using the same device. The system has three main components: an electrode that stimulates, records and monitors brain activity with the capability to also perform an ablation, a temperature probe, and a radio frequency heat generator system.
"It was my pleasure to take part in this engaging conversation with Elizabeth Hart and Dr. Clark about the latest treatment options for epilepsy. The OneRF® system represents a significant advancement, offering a more efficient and precise approach for patients who still experience seizure activity after using traditional medication options," said Dave Rosa, CEO of NeuroOne. "By combining real-time monitoring with targeted ablation in a single procedure, we are not only improving patient outcomes but also reducing the need for multiple invasive surgeries."
To learn more about NeuroOne and its groundbreaking work in epilepsy treatment, as well as the potential for our OneRF® platform to be used in pain management, please visit nmtc1.com.
About NeuroOne
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential for our OneRF® platform to be used in pain management our business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
Caution: Federal law restricts this device to sale by or on the order of a physician.
IR Contact
Chris Donovan
MZ Group – MZ North America
(914) 352-5853
NMTC@mzgroup.us
FAQ
What makes NeuroOne's OneRF® Ablation System unique for epilepsy treatment?
How many components does the NMTC OneRF® system include?
What market size is NMTC's OneRF® system targeting in epilepsy treatment?
What additional applications is NMTC exploring for the OneRF® platform?
